TORONTO, May 22, 2025 /CNW/ - Neighbourly Pharmacy is proud to mark a decade of care, connection, and growth. On March 20, 2025, the company celebrated its 10-year anniversary, honouring the incredible journey from a single location into a trusted, coast-to-coast network of pharmacies, committed to enhancing the health and well-being of our customers. The celebration continues throughout the year as Neighbourly reflects on its roots and looks ahead to a vibrant future.
"As we celebrate 10 incredible years, I find myself reflecting on the journey that brought us here," said Skip Bourdo, CEO of Neighbourly Pharmacy. "One of my fondest memories from my first six months is traveling across this beautiful country, visiting over 100 stores, and meeting the talented team members who bring our mission to life every day. Witnessing firsthand the impact we have on the communities we serve was both humbling and inspiring. That experience shaped our tagline: Kindness in Every Community.
This milestone belongs to all of us. Our dedicated teams, our loyal customers, and the communities that welcome us with open arms, thank you for being part of our story. Here's to the next 10 years of making a difference, together!"
Over the past decade, Neighbourly has become a recognized leader in Canadian pharmacy, known for its strong community connection, responsible acquisition model that honours the legacy of independent pharmacies, and a steadfast commitment to hiring and retaining top talent. With its pharmacies spanning rural, remote, suburban and urban communities across Canada, Neighbourly's reach, and reputation have solidified its place as a trusted health care provider, rooted in care, powered by people, and built with purpose.
At the heart of this success is Neighbourly's pharmacist-led model, with pharmacists playing central roles across operations and strategy. This includes recent leadership changes designed to support the Company's next phase of growth.
Strengthening Leadership for the Next Decade
In addition to our anniversary celebration, Neighbourly is pleased to announce the following key leadership promotions to support our continued growth and commitment to excellence, with a focus on Pharmacy first and pharmacist-led operations.
Alicia Matthews-Kent has been promoted to Chief Operating Officer (COO). Alicia, a pharmacist and proven leader in health care, joined Neighbourly in 2023. She will oversee operations and pharmacy strategy while ensuring alignment across our business.
Michael Helbrecht joined Neighbourly in 2024 and has been promoted to Senior Vice President, National Operations. Michael will oversee total-box operations across Canada, including merchandising, marketing and asset protection. Reporting to Alicia, he will be responsible for ensuring that our pharmacies are supported, aligned, and performing consistently at a high level across the country.
As part of this structure, the following recent leadership changes have been made to strengthen our regional operations. Each Regional Vice President reporting directly to Michael is a pharmacist and supports our pharmacist-led operations strategy:
"These leadership promotions position us well for the future—ensuring strong execution, continued innovation, and a clear path for continued growth and expansion," said Skip Bourdo. "Our next decade will continue to be defined by our mission: To elevate individual and community wellness through unmatched care and kindness."
About Neighbourly Pharmacy
Neighbourly is Canada's largest and fastest growing network of community pharmacies. United by their patient-first focus and their role as essential and trusted healthcare hubs within their communities, Neighbourly Pharmacy strives to provide accessible healthcare with a personal touch. Since 2015, Neighbourly has expanded its diversified national footprint to include over 300 locations across Canada, reinforcing the Company's reputation as the industry's acquirer of choice.
February 13, 2024 January 23, 2024 January 15, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load